Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 Nov 25

PMID 38004506

Authors

Melpomeni Peppa

Aspasia Manta

Ioanna Mavroeidi

Athina Asimakopoulou

Alexandros Syrigos

Constantinos Nastos

Emmanouil Pikoulis

Anastasios Kollias

Affiliations

Soon will be listed here.

Abstract

Type 2 diabetes mellitus is a major health problem worldwide with a steadily increasing prevalence reaching epidemic proportions. The major concern is the increased morbidity and mortality due to diabetic complications. Traditional but also nontraditional risk factors have been proposed to explain the pathogenesis of type 2 diabetes mellitus and its complications. Hyperglycemia has been considered an important risk factor, and the strict glycemic control can have a positive impact on microangiopathy but not macroangiopathy and its related morbidity and mortality. Thus, the therapeutic algorithm has shifted focus from a glucose-centered approach to a strategy that now emphasizes target-organ protection. Sodium-glucose transporter 2 inhibitors is an extremely important class of antidiabetic medications that, in addition to their glucose lowering effect, also exhibit cardio- and renoprotective effects. Various established and novel biomarkers have been described, reflecting kidney and cardiovascular function. In this review, we investigated the changes in established but also novel biomarkers of kidney, heart and vascular function associated with sodium-glucose transporter 2 inhibitors treatment in patients with type 2 diabetes mellitus.

References

Suhrs H, Nilsson M, Bove K, Zander M, Prescott E . Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus-A randomized, placebo-controlled cross-over study. PLoS One. 2022; 17(2):e0263481. PMC: 8836314. DOI: 10.1371/journal.pone.0263481. View

Carbone S, Billingsley H, Canada J, Bressi E, Rotelli B, Kadariya D . The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study. Diabetes Metab Res Rev. 2020; 36(8):e3335. PMC: 7685099. DOI: 10.1002/dmrr.3335. View

von Lewinski D, Tripolt N, Sourij H, Pferschy P, Oulhaj A, Alber H . Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) - A phase III study. Am Heart J. 2022; 246:152-160. DOI: 10.1016/j.ahj.2022.01.008. View

Dekkers C, Petrykiv S, Laverman G, Cherney D, Gansevoort R, Heerspink H . Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018; 20(8):1988-1993. PMC: 6055757. DOI: 10.1111/dom.13301. View

Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y . Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial. Cardiovasc Diabetol. 2021; 20(1):4. PMC: 7784389. DOI: 10.1186/s12933-020-01206-1. View

Chilton R, Tikkanen I, Cannon C, Crowe S, Woerle H, Broedl U . Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015; 17(12):1180-93. PMC: 5057299. DOI: 10.1111/dom.12572. View

Ni L, Yuan C, Chen G, Zhang C, Wu X . SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020; 19(1):98. PMC: 7320582. DOI: 10.1186/s12933-020-01071-y. View

Tanaka A, Sata M, Okada Y, Teragawa H, Eguchi K, Shimabukuro M . Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial. Eur Heart J Cardiovasc Pharmacother. 2022; 9(2):165-172. PMC: 9892869. DOI: 10.1093/ehjcvp/pvac059. View

Nedosugova L, Markina Y, Bochkareva L, Kuzina I, Petunina N, Yudina I . Inflammatory Mechanisms of Diabetes and Its Vascular Complications. Biomedicines. 2022; 10(5). PMC: 9138517. DOI: 10.3390/biomedicines10051168. View

10.

Lastra G, Syed S, Kurukulasuriya L, Manrique C, Sowers J . Type 2 diabetes mellitus and hypertension: an update. Endocrinol Metab Clin North Am. 2014; 43(1):103-22. PMC: 3942662. DOI: 10.1016/j.ecl.2013.09.005. View

11.

Sawada T, Uzu K, Hashimoto N, Onishi T, Takaya T, Shimane A . Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease. J Atheroscler Thromb. 2019; 27(7):644-656. PMC: 7406405. DOI: 10.5551/jat.50807. View

12.

Berg D, Docherty K, Sattar N, Jarolim P, Welsh P, Jhund P . Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation. 2021; 145(3):158-169. DOI: 10.1161/CIRCULATIONAHA.121.057852. View

13.

Eickhoff M, Olsen F, Frimodt-Moller M, Diaz L, Faber J, Jensen M . Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria - A double blind randomized placebo-controlled crossover trial. J Diabetes Complications. 2020; 34(7):107590. DOI: 10.1016/j.jdiacomp.2020.107590. View

14.

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

15.

Correale M, Mazzeo P, Mallardi A, Leopizzi A, Tricarico L, Fortunato M . Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure. Cardiovasc Drugs Ther. 2021; 36(6):1157-1164. PMC: 9652233. DOI: 10.1007/s10557-021-07254-3. View

16.

DeLeon-Pennell K, Meschiari C, Jung M, Lindsey M . Matrix Metalloproteinases in Myocardial Infarction and Heart Failure. Prog Mol Biol Transl Sci. 2017; 147:75-100. PMC: 5576003. DOI: 10.1016/bs.pmbts.2017.02.001. View

17.

Daniels L, Maisel A . Natriuretic peptides. J Am Coll Cardiol. 2007; 50(25):2357-68. DOI: 10.1016/j.jacc.2007.09.021. View

18.

Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

19.

Omar M, Jensen J, Ali M, Frederiksen P, Kistorp C, Videbaek L . Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial. JAMA Cardiol. 2021; 6(7):836-840. PMC: 7788505. DOI: 10.1001/jamacardio.2020.6827. View

20.

Jensen J, Omar M, Kistorp C, Poulsen M, Tuxen C, Gustafsson I . Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial. Am Heart J. 2020; 228:47-56. DOI: 10.1016/j.ahj.2020.07.011. View